Pulmonary Hypertension: No Reason for TAVR Contraindication

In most severe aortic stenosis patients with pulmonary hypertension, transcatheter aortic valve replacement (TAVR) reduced pulmonary systolic pressure.

There patients presented lower risk and lower all-cause mortality at short, median and long term. This data show that pulmonary hypertension should not be a TAVR contraindication.

Pulmonary hypertension is common among TAVR patients. The most frequent treatment is associated to hypotension regression, even though regression predictors and prognosis remain unknown.

This study included 617 consecutive patients undergoing TAVR between 2009 and 2015, stratified in terciles according to baseline pulmonary artery systolic pressure, resulting in: normal (PASP <34 mm Hg), mild to moderate (34 mm Hg ≤ PASP 46 mm Hg) and severe pulmonary hypertension (PASP ≥46 mm Hg). After TAVR, 520 patients with pulmonary hypertension at discharge were re-stratified according to presence or absence of pulmonary hypertension reduction.


Read also: Low-Risk TAVR Trending in All Papers.


Primary endpoint was all cause mortality at 30 days, one year and 5.9 long term follow up.

Patients with mild to moderate baseline pulmonary hypertension showed significant reduction at discharge and at one year. All-cause mortality risk resulted similar in all patients with baseline pulmonary hypertension in all time intervals.

After TAVR, nearly half of patients (46%) showed a significant reduction of pulmonary hypertension.

The opposite occurred with patients with residual pulmonary hypertension where mortality at 30 days (HR: 3.49; p<0.001) and one year (HR: 2.47; p<0.001) was quite higher.


Read also: Safe for 80-Year-Olds. Should Nonagenarians be Withheld from TAVR?


Left ventricular ejection fraction >40%, severe baseline pulmonary hypertension, the absence of mild to moderate concomitant tricuspid failure and EuroSCORE log <25 were independent predictors of pulmonary hypertension reduction.

Conclusion

Many patients undergoing TAVR present concomitant pulmonary hypertension and this procedure was associated with significant pulmonary hypertension reduction at short and long term. Patients who saw pulmonary hypertension reduction also saw mortality reduction at short mid and long term. The presence of pulmonary hypertension should not contraindicate transcatheter aortic valve replacement.

Original Title: Pulmonary Hypertension in Patients With Severe Aortic Stenosis: Prognostic Impact After Transcatheter Aortic Valve Replacement. Pulmonary Hypertension in Patients Undergoing TAVR.

Reference: Brunilda Alushi et al. JACC Cardiovasc Imaging. 2019 Apr;12(4):591-601.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....